Madrigal shares hit 52-week low on doubts over durable profitability
Madrigal reported its first quarterly profit, but management warned it may not last near term. MDGL shares fell to a one-year low, according to Stocktwits.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Stocktwits, shares of Madrigal Pharmaceuticals (MDGL) fell on Tuesday to a new 52-week low, even though the company reported its first quarterly profit. Investors focused on management's warning that profitability may not hold in the near term because of ongoing commercial spending. At the time of writing, the stock was down 6%.
Third-quarter net sales rose 50% year over year to $431.3 million. Diluted earnings per share were $1.83, against a loss of $4.01 a year earlier and an analyst estimate of a $0.87 loss per share. More than 55,850 patients were on Rezdiffra at quarter-end, nearly double the year-ago figure. Net income reached $55.4 million, and cash stood at $961.8 million.
why it matters
The reaction suggests the market is weighing the durability of profits, not just the headline quarter. The CFO said the company may dip in and out of profitability, depending on investment timing. Citi kept a Buy rating and raised its price target to $760 from $725, yet the shares are down 31% year to date.
market impact
MDGL shares: strong sales offset by a warning on unstable profits, pressure on the stock.
- MDGL mixed — strong sales and patient growth support the stock, while the warning on unstable profit weighs on it
tags
instruments
sources
- MDGL Stock Hits Fresh 52-Week Low On Near-Term Profitability Concerns, But Citi Sees Over 75% Upside — Stocktwits, 3 November 2026 at 20:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗